Natriumoxybat (Sodium Oxybate)

Sodium oxybate acts as an agonist at gamma‑hydroxybutyrate (GHB) receptors and modulates GABA_B receptors in the central nervous system. This dual activity enhances inhibitory neurotransmission, promotes slow‑wave sleep, and stabilizes sleep architecture, thereby decreasing cataplexy episodes and excessive daytime sleepiness.

The appropriate dose of Natriumoxybat is determined individually by a qualified prescriber based on the patient’s clinical condition, response, and tolerability. Dosing regimens are tailored during titration and should follow the prescribing information provided by the healthcare professional.

Sodium oxybate is generally contraindicated in pregnancy because potential fetal risks have not been fully established. Likewise, it is not recommended for breastfeeding mothers, as the drug may be excreted in breast milk and could affect the infant. Alternative therapies should be considered.

To request Natriumoxybat, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Sodium oxybate is the only medication approved specifically for cataplexy, offering a unique mechanism that improves both nighttime sleep and daytime symptoms. Other agents, such as modafinil or pitolisant, primarily target excessive daytime sleepiness and do not address cataplexy as effectively as sodium oxybate.

Natriumoxybat should be stored at ambient temperature below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Natriumoxybat is taken orally, usually as a liquid solution, in divided doses during the night as directed by the prescribing physician. It is important to follow the exact dosing schedule and to avoid missing doses, as abrupt discontinuation can affect sleep patterns.

The most serious risks include respiratory depression, seizures, severe hypotension, and the potential for abuse or dependence. Patients should be monitored closely for signs of respiratory compromise, especially when initiating therapy or when combined with other central nervous system depressants.

Natriumoxybat is contraindicated in individuals with severe obstructive sleep apnea, uncontrolled respiratory disorders, known hypersensitivity to sodium oxybate, pregnant or breastfeeding women, and patients taking alcohol or other potent CNS depressants without medical supervision.